Sees FY23 adjusted EBITDA $85M-$93M. "Assertio’s successful achievement of its strategic priorities in 2022 delivered financial results that exceeded our outlook quarter after quarter, culminating in an especially strong fourth quarter as we shifted Indocin demand in favor of higher margin commercial purchases," said Dan Peisert, CEO. "The fourth quarter was a springboard into 2023 where we see opportunities to increase sales in our key Indocin, Sympazan and Otrexup assets, which we expect will offset the January loss of exclusivity on Cambia. Our life cycle management program for Indocin will be one of our key priorities for 2023 as we seek to access a larger addressable market. Later this year, we expect to be enrolling patients into a clinical trial that is currently being designed to expand the label and, if approved, to provide regulatory exclusivity."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASRT:
- Assertio Reports Fourth Quarter and Full Year 2022 Financial Results
- Assertio Holdings appoints Howard Franklin as SVP, medical
- Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical
- Assertio Holdings price target raised to $8 from $6 at BWS Financial
- Assertio Holdings announces exchange offer of $30M of senior notes